Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT201 + PD-1 Inhibitor in Advanced Head and Neck Tumors
NCT06190275Recruiting
- Sponsor
- Grit Biotechnology
- Start
- May 2024
- Primary completion
- Apr 2027
- Modality
- Gene Editing, Gene Silencing, Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Open-label, single-arm trial of GT201 in head and neck squamous cell carcinoma (HNSCC), sponsored by Grit Biotechnology. Primary endpoint: Incidence and severity of adverse events at 3 years. Started May 2024; status: recruiting.
02
Drugs
GT201
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06190275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06190275.